511 related articles for article (PubMed ID: 20924075)
1. Double heterozygosity in the BRCA1 and BRCA2 genes in the Jewish population.
Lavie O; Narod S; Lejbkowicz F; Dishon S; Goldberg Y; Gemer O; Rennert G
Ann Oncol; 2011 Apr; 22(4):964-966. PubMed ID: 20924075
[TBL] [Abstract][Full Text] [Related]
2. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families.
Levy-Lahad E; Catane R; Eisenberg S; Kaufman B; Hornreich G; Lishinsky E; Shohat M; Weber BL; Beller U; Lahad A; Halle D
Am J Hum Genet; 1997 May; 60(5):1059-67. PubMed ID: 9150153
[TBL] [Abstract][Full Text] [Related]
3. Differences in the characteristics of families with BRCA1 and BRCA2 mutations in Israel.
Rennert G; Dishon S; Rennert HS; Fares F
Eur J Cancer Prev; 2005 Aug; 14(4):357-61. PubMed ID: 16030426
[TBL] [Abstract][Full Text] [Related]
4. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
5. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
Hamel N; Kotar K; Foulkes WD
BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
[TBL] [Abstract][Full Text] [Related]
6. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer.
Moslehi R; Chu W; Karlan B; Fishman D; Risch H; Fields A; Smotkin D; Ben-David Y; Rosenblatt J; Russo D; Schwartz P; Tung N; Warner E; Rosen B; Friedman J; Brunet JS; Narod SA
Am J Hum Genet; 2000 Apr; 66(4):1259-72. PubMed ID: 10739756
[TBL] [Abstract][Full Text] [Related]
7. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2.
Roa BB; Boyd AA; Volcik K; Richards CS
Nat Genet; 1996 Oct; 14(2):185-7. PubMed ID: 8841191
[TBL] [Abstract][Full Text] [Related]
8. Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers.
Finkelman BS; Rubinstein WS; Friedman S; Friebel TM; Dubitsky S; Schonberger NS; Shoretz R; Singer CF; Blum JL; Tung N; Olopade OI; Weitzel JN; Lynch HT; Snyder C; Garber JE; Schildkraut J; Daly MB; Isaacs C; Pichert G; Neuhausen SL; Couch FJ; van't Veer L; Eeles R; Bancroft E; Evans DG; Ganz PA; Tomlinson GE; Narod SA; Matloff E; Domchek S; Rebbeck TR
J Clin Oncol; 2012 Apr; 30(12):1321-8. PubMed ID: 22430266
[TBL] [Abstract][Full Text] [Related]
9. Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families.
Cierniková S; Tomka M; Kovác M; Stevurková V; Zajac V
Neoplasma; 2006; 53(2):97-102. PubMed ID: 16575464
[TBL] [Abstract][Full Text] [Related]
10. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women.
Abeliovich D; Kaduri L; Lerer I; Weinberg N; Amir G; Sagi M; Zlotogora J; Heching N; Peretz T
Am J Hum Genet; 1997 Mar; 60(3):505-14. PubMed ID: 9042909
[TBL] [Abstract][Full Text] [Related]
11. High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma.
Biron-Shental T; Drucker L; Altaras M; Bernheim J; Fishman A
Eur J Surg Oncol; 2006 Dec; 32(10):1097-100. PubMed ID: 16650962
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for detecting germline BRCA1 and BRCA2 founder mutations in Ashkenazi Jewish women with breast or ovarian cancer.
Hodgson SV; Heap E; Cameron J; Ellis D; Mathew CG; Eeles RA; Solomon E; Lewis CM
J Med Genet; 1999 May; 36(5):369-73. PubMed ID: 10353781
[TBL] [Abstract][Full Text] [Related]
13. Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies.
Antoniou AC; Pharoah PD; Narod S; Risch HA; Eyfjord JE; Hopper JL; Olsson H; Johannsson O; Borg A; Pasini B; Radice P; Manoukian S; Eccles DM; Tang N; Olah E; Anton-Culver H; Warner E; Lubinski J; Gronwald J; Gorski B; Tulinius H; Thorlacius S; Eerola H; Nevanlinna H; Syrjäkoski K; Kallioniemi OP; Thompson D; Evans C; Peto J; Lalloo F; Evans DG; Easton DF
J Med Genet; 2005 Jul; 42(7):602-3. PubMed ID: 15994883
[TBL] [Abstract][Full Text] [Related]
14. The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews.
Hartge P; Struewing JP; Wacholder S; Brody LC; Tucker MA
Am J Hum Genet; 1999 Apr; 64(4):963-70. PubMed ID: 10090881
[TBL] [Abstract][Full Text] [Related]
15. The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel.
Vazina A; Baniel J; Yaacobi Y; Shtriker A; Engelstein D; Leibovitz I; Zehavi M; Sidi AA; Ramon Y; Tischler T; Livne PM; Friedman E
Br J Cancer; 2000 Aug; 83(4):463-6. PubMed ID: 10945492
[TBL] [Abstract][Full Text] [Related]
16. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Offit K; Foulkes W; Robson ME; Wacholder S; Eng CM; Karp SE; Begg CB
Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):467-73. PubMed ID: 11352856
[TBL] [Abstract][Full Text] [Related]
17. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.
Struewing JP; Hartge P; Wacholder S; Baker SM; Berlin M; McAdams M; Timmerman MM; Brody LC; Tucker MA
N Engl J Med; 1997 May; 336(20):1401-8. PubMed ID: 9145676
[TBL] [Abstract][Full Text] [Related]
18. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2.
Gabai-Kapara E; Lahad A; Kaufman B; Friedman E; Segev S; Renbaum P; Beeri R; Gal M; Grinshpun-Cohen J; Djemal K; Mandell JB; Lee MK; Beller U; Catane R; King MC; Levy-Lahad E
Proc Natl Acad Sci U S A; 2014 Sep; 111(39):14205-10. PubMed ID: 25192939
[TBL] [Abstract][Full Text] [Related]
19. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%.
Oddoux C; Struewing JP; Clayton CM; Neuhausen S; Brody LC; Kaback M; Haas B; Norton L; Borgen P; Jhanwar S; Goldgar D; Ostrer H; Offit K
Nat Genet; 1996 Oct; 14(2):188-90. PubMed ID: 8841192
[TBL] [Abstract][Full Text] [Related]
20. Analysis of BRCA1/BRCA2 genes' contribution to breast cancer susceptibility in high risk Jewish Ashkenazi women.
Distelman-Menachem T; Shapira T; Laitman Y; Kaufman B; Barak F; Tavtigian S; Friedman E
Fam Cancer; 2009; 8(2):127-33. PubMed ID: 18798010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]